Hypoxia‐inducible factor‐targeting prodrug TOP3 combined with gemcitabine or TS‐1 improves pancreatic cancer survival in an orthotopic model

Pancreatic cancer is one of the most lethal digestive system cancers with a 5‐year survival rate of 4–7%. Despite extensive efforts, recent chemotherapeutic regimens have provided only limited benefits to pancreatic cancer patients. Gemcitabine and TS‐1, the current standard‐of‐care chemotherapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoang, Ngoc Thi Hong, Kadonosono, Tetsuya, Kuchimaru, Takahiro, Kizaka‐Kondoh, Shinae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982586/
https://www.ncbi.nlm.nih.gov/pubmed/27270607
http://dx.doi.org/10.1111/cas.12982

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982586/
https://www.ncbi.nlm.nih.gov/pubmed/27270607
http://dx.doi.org/10.1111/cas.12982

Ejemplares similares